Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(0.80)
# 4,102
Out of 4,692 analysts
132
Total ratings
39.8%
Success rate
-2.5%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRVE Braveheart Bio | Initiated Coverage: Buy | $40 | $25.50 | +56.86% | 1 | Aug 31, 2026 | |
| MIST Milestone Pharmaceuticals | Initiated Coverage: Buy | $3 | $1.16 | +158.62% | 1 | Aug 20, 2026 | |
| QNCX Quince Therapeutics | Reiterated: Buy | $80 → $70 | $32.57 | +114.92% | 2 | Aug 17, 2026 | |
| INSM Insmed | Maintained: Buy | $235 | $121.82 | +92.91% | 5 | Aug 6, 2026 | |
| VNDA Vanda Pharmaceuticals | Reiterated: Buy | $11 | $5.40 | +103.70% | 6 | Aug 6, 2026 | |
| MNKD MannKind | Maintained: Buy | $9 → $8 | $4.01 | +99.50% | 5 | Aug 5, 2026 | |
| TENX Tenax Therapeutics | Maintained: Buy | $35 | $1.84 | +1,802.17% | 3 | Jul 29, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $2.20 | +81.82% | 1 | May 21, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $4 | $2.31 | +73.16% | 2 | May 18, 2026 | |
| PTHS Pelthos Therapeutics | Initiated Coverage: Buy | $50 | $24.08 | +107.64% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $3.36 | +257.14% | 5 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.17 | - | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $525 → $625 | $510.38 | +22.46% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $85 | $65.23 | +30.31% | 18 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $450 → $400 | $240.69 | +66.19% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $544.52 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $405 → $340 | $429.88 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 → $55 | $66.81 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $70 → $80 | $146.34 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $795 → $925 | $799.08 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $10 | $16.11 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $18.79 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $56.98 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $5.21 | n/a | 4 | Mar 20, 2023 |
Braveheart Bio
Aug 31, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $25.50
Upside: +56.86%
Milestone Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $3
Current: $1.16
Upside: +158.62%
Quince Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $80 → $70
Current: $32.57
Upside: +114.92%
Insmed
Aug 6, 2026
Maintained: Buy
Price Target: $235
Current: $121.82
Upside: +92.91%
Vanda Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $11
Current: $5.40
Upside: +103.70%
MannKind
Aug 5, 2026
Maintained: Buy
Price Target: $9 → $8
Current: $4.01
Upside: +99.50%
Tenax Therapeutics
Jul 29, 2026
Maintained: Buy
Price Target: $35
Current: $1.84
Upside: +1,802.17%
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.20
Upside: +81.82%
Inhibikase Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $4
Current: $2.31
Upside: +73.16%
Pelthos Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $24.08
Upside: +107.64%
Mar 20, 2026
Maintained: Buy
Price Target: $10 → $12
Current: $3.36
Upside: +257.14%
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.17
Upside: -
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $510.38
Upside: +22.46%
Mar 2, 2026
Maintained: Buy
Price Target: $85
Current: $65.23
Upside: +30.31%
Feb 12, 2026
Maintained: Hold
Price Target: $450 → $400
Current: $240.69
Upside: +66.19%
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $544.52
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $405 → $340
Current: $429.88
Upside: n/a
Feb 4, 2025
Maintained: Hold
Price Target: $52 → $55
Current: $66.81
Upside: n/a
Nov 6, 2024
Maintained: Hold
Price Target: $70 → $80
Current: $146.34
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: $795 → $925
Current: $799.08
Upside: n/a
Feb 23, 2024
Maintained: Buy
Price Target: $15 → $10
Current: $16.11
Upside: n/a
Nov 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $18.79
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $56.98
Upside: n/a
Mar 20, 2023
Maintained: Hold
Price Target: $3
Current: $5.21
Upside: n/a